These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24926868)

  • 1. The importance of serotonin and noradrenaline in anxiety.
    Blier P; El Mansari M
    Int J Psychiatry Clin Pract; 2007; 11 Suppl 2():16-23. PubMed ID: 24926868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escitalopram: a unique mechanism of action.
    Bræstrup C; Sanchez C
    Int J Psychiatry Clin Pract; 2004; 8 Suppl 1():11-3. PubMed ID: 24930683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
    Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
    Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder.
    el Mansari M; Bouchard C; Blier P
    Neuropsychopharmacology; 1995 Oct; 13(2):117-27. PubMed ID: 8597523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for OCD.
    Fineberg NA
    Int J Psychiatry Clin Pract; 2007; 11 Suppl 2():24-30. PubMed ID: 24926869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.
    Nguyen HT; Guiard BP; Bacq A; David DJ; David I; Quesseveur G; Gautron S; Sanchez C; Gardier AM
    Br J Pharmacol; 2013 Jan; 168(1):103-16. PubMed ID: 22233336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram for the treatment of major depression and anxiety disorders.
    Höschl C; Svestka J
    Expert Rev Neurother; 2008 Apr; 8(4):537-52. PubMed ID: 18416657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escitalopram: a second-generation SSRI.
    Owens MJ; Rosenbaum JF
    CNS Spectr; 2002 Apr; 7(4 Suppl 1):34-9. PubMed ID: 15131491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An emerging role for escitalopram in the treatment of obsessive-compulsive disorder.
    Hedges DW; Woon FL
    Neuropsychiatr Dis Treat; 2007 Aug; 3(4):455-61. PubMed ID: 19300574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiety and depression: individual entities or two sides of the same coin?
    Nutt D
    Int J Psychiatry Clin Pract; 2004; 8 Suppl 1():19-24. PubMed ID: 24930685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats.
    Mørk A; Kreilgaard M; Sánchez C
    Neuropharmacology; 2003 Aug; 45(2):167-73. PubMed ID: 12842122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escitalopram: a review of its use in the management of anxiety disorders.
    Dhillon S; Scott LJ; Plosker GL
    CNS Drugs; 2006; 20(9):763-90. PubMed ID: 16953656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders.
    Humble M; Wistedt B
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 5():21-39. PubMed ID: 1431019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors.
    Ceglia I; Acconcia S; Fracasso C; Colovic M; Caccia S; Invernizzi RW
    Br J Pharmacol; 2004 Jun; 142(3):469-78. PubMed ID: 15148253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Escitalopram and citalopram: the unexpected role of the R-enantiomer].
    Jacquot C; David DJ; Gardier AM; Sánchez C
    Encephale; 2007; 33(2):179-87. PubMed ID: 17675913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors.
    Szabo ST; de Montigny C; Blier P
    Int J Neuropsychopharmacol; 2000 Mar; 3(1):1-11. PubMed ID: 11343573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder.
    Bergqvist PB; Bouchard C; Blier P
    Biol Psychiatry; 1999 Jan; 45(2):164-74. PubMed ID: 9951563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiety disorders: under-diagnosed and insufficiently treated.
    Kasper S
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():3-9. PubMed ID: 24931537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram: A New SSRI for the Treatment of Depression in Primary Care.
    Culpepper L
    Prim Care Companion J Clin Psychiatry; 2002 Dec; 4(6):209-214. PubMed ID: 15014711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity.
    Vahid-Ansari F; Zhang M; Zahrai A; Albert PR
    Front Neurosci; 2019; 13():404. PubMed ID: 31114473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.